Press Releases

May 08, 2025

New Data Show Delve Bio’s Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test

BUSINESS WIRE

April 07, 2025

Delve Bio to Present on Metagenomic Next Generation Sequencing (mNGS) at the American Academy of Neurology 2025 Annual Meeting

BUSINESS WIRE

December 04, 2024

Delve Bio Announces Launch of its Groundbreaking Genomic Infectious Disease Test, Delve Detect

BUSINESS WIRE

November 21, 2024

Delve Bio Presents Data Showing Metagenomic Next-Generation Sequencing (mNGS) Delivers Greater Diagnostic Yield Than Conventional Methods in Central Nervous System Infections

BUSINESS WIRE

November 12, 2024

Delve Bio and UCSF Publish Research Demonstrating Clinical Utility of Metagenomic Next-Generation Sequencing (mNGS) for Diagnosing Serious Neurological Infections

BUSINESS WIRE

October 09, 2024

Delve Bio Announces Partnership with Broad Clinical Labs for Metagenomic Next Generation Sequencing (mNGS)

BUSINESS WIRE

June 17, 2024

Delve Bio Announces Clinical Data on the Use of Metagenomic Next-Generation Sequencing (mNGS) to Identify Pathogens Causing Central Nervous System Infections

BUSINESS WIRE

April 17, 2024

Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections

BUSINESS WIRE

June 20, 2023

Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis

BUSINESS WIRE

For inquiries, please visit our contact page.
Contact Us